LBPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LBPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Longboard Pharmaceuticals's Enterprise Value is $487.37 Mil. Longboard Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-52.95 Mil. Therefore, Longboard Pharmaceuticals's EV-to-FCF for today is -9.20.
The historical rank and industry rank for Longboard Pharmaceuticals's EV-to-FCF or its related term are showing as below:
During the past 4 years, the highest EV-to-FCF of Longboard Pharmaceuticals was 2.42. The lowest was -17.49. And the median was 0.00.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-18), Longboard Pharmaceuticals's stock price is $20.69. Longboard Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-2.240. Therefore, Longboard Pharmaceuticals's PE Ratio for today is At Loss.
The historical data trend for Longboard Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longboard Pharmaceuticals Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EV-to-FCF | - | 0.93 | 0.28 | -1.96 |
Longboard Pharmaceuticals Quarterly Data | |||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-FCF | Get a 7-Day Free Trial | -0.40 | -2.30 | -1.56 | -1.96 | -9.87 |
For the Biotechnology subindustry, Longboard Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Longboard Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Longboard Pharmaceuticals's EV-to-FCF falls into.
Longboard Pharmaceuticals's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 487.367 | / | -52.948 | |
= | -9.20 |
Longboard Pharmaceuticals's current Enterprise Value is $487.37 Mil.
Longboard Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longboard Pharmaceuticals (NAS:LBPH) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Longboard Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 20.69 | / | -2.240 | |
= | At Loss |
Longboard Pharmaceuticals's share price for today is $20.69.
Longboard Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.240.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Longboard Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Randall Kaye | officer: CMO | 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121 |
Jane Tiller | director | C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037 |
Brandi Roberts | officer: Chief Financial Officer | 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130 |
Phillip M Schneider | director | GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121 |
Vincent Aurentz | director | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Kevin Robert Lind | director, officer: President and CEO | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Paul J Sekhri | director | C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588 |
Casey Lynch | director | C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Le Goff Corinne | director | 200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139 |
Arena Pharmaceuticals Inc | 10 percent owner | 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Philip Perera | officer: Chief Medical Officer | C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
From GuruFocus
By Business Wire Business Wire • 12-05-2022
By Business Wire • 08-30-2023
By Business Wire Business Wire • 02-08-2023
By Business Wire • 08-23-2023
By Ds*** Ds*** • 09-01-2022
By Business Wire Business Wire • 02-23-2023
By Business Wire • 08-31-2023
By Business Wire Business Wire • 11-29-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocus Research • 11-14-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.